PortfoliosLab logoPortfoliosLab logo
NICE vs. GMED
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NICE vs. GMED - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in NICE Ltd. (NICE) and Globus Medical, Inc. (GMED). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NICE achieves a -11.77% return, which is significantly lower than GMED's -10.54% return. Over the past 10 years, NICE has underperformed GMED with an annualized return of 4.49%, while GMED has yielded a comparatively higher 12.07% annualized return.


NICE

1D
1.92%
1M
13.24%
6M
-14.80%
YTD
-11.77%
1Y
-35.59%
3Y*
-21.22%
5Y*
-17.19%
10Y*
4.49%

GMED

1D
1.92%
1M
-2.99%
6M
-17.32%
YTD
-10.54%
1Y
36.75%
3Y*
8.91%
5Y*
-0.63%
10Y*
12.07%
*Multi-year figures are annualized to reflect compound growth (CAGR)

NICE vs. GMED - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NICE
NICE Ltd.
-11.77%-33.44%-14.87%3.75%-36.66%7.07%82.75%43.38%17.73%33.92%
GMED
Globus Medical, Inc.
-10.54%5.56%55.21%-28.25%2.87%10.70%10.77%36.04%5.30%65.66%

Correlation

The correlation between NICE and GMED is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.17

Correlation (3Y)
Calculated over the trailing 3-year period

0.25

Correlation (5Y)
Calculated over the trailing 5-year period

0.31

Correlation (10Y)
Calculated over the trailing 10-year period

0.30

Correlation (All Time)
Calculated using the full available price history since Aug 3, 2012

0.28

The correlation between NICE and GMED shifts across timeframes, from 0.17 (1 year) to 0.31 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

NICE:

$5.84B

GMED:

$10.53B

EPS

NICE:

$8.52

GMED:

$4.28

PE Ratio

NICE:

11.70

GMED:

18.23

PEG Ratio

NICE:

0.35

GMED:

0.19

PS Ratio

NICE:

2.06

GMED:

3.45

PB Ratio

NICE:

1.64

GMED:

2.28

Total Revenue (TTM)

NICE:

$3.01B

GMED:

$3.10B

Gross Profit (TTM)

NICE:

$1.98B

GMED:

$1.58B

EBITDA (TTM)

NICE:

$841.27M

GMED:

$803.34M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NICE vs. GMED — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NICE
NICE Risk / Return Rank: 1414
Overall Rank
NICE Sharpe Ratio Rank: 1212
Sharpe Ratio Rank
NICE Sortino Ratio Rank: 1515
Sortino Ratio Rank
NICE Omega Ratio Rank: 1313
Omega Ratio Rank
NICE Calmar Ratio Rank: 1515
Calmar Ratio Rank
NICE Martin Ratio Rank: 1616
Martin Ratio Rank

GMED
GMED Risk / Return Rank: 7373
Overall Rank
GMED Sharpe Ratio Rank: 6969
Sharpe Ratio Rank
GMED Sortino Ratio Rank: 7575
Sortino Ratio Rank
GMED Omega Ratio Rank: 7272
Omega Ratio Rank
GMED Calmar Ratio Rank: 7575
Calmar Ratio Rank
GMED Martin Ratio Rank: 7575
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NICE vs. GMED - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for NICE Ltd. (NICE) and Globus Medical, Inc. (GMED). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


NICEGMEDDifference
Sharpe ratioReturn per unit of total volatility

-1.47

Sortino ratioReturn per unit of downside risk

-2.64

Omega ratioGain probability vs. loss probability

0.87

1.21

-0.34

Calmar ratioReturn relative to maximum drawdown

-0.76

1.60

-2.36

Martin ratioReturn relative to average drawdown

-1.20

3.87

-5.06

NICE vs. GMED - Sharpe Ratio Comparison

The current NICE Sharpe Ratio is -0.76, which is lower than the GMED Sharpe Ratio of 0.71. The chart below compares the historical Sharpe Ratios of NICE and GMED, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

NICE vs. GMED - Drawdown Comparison

The maximum NICE drawdown since its inception was -93.23%, which is greater than GMED's maximum drawdown of -47.91%. Use the drawdown chart below to compare losses from any high point for NICE and GMED.


Loading charts...

Drawdown Indicators


NICEGMEDDifference

Max Drawdown

Largest peak-to-trough decline

-93.23%

-47.91%

-45.32%

Max Drawdown (1Y)

Largest decline over 1 year

-51.19%

-22.10%

-29.09%

Max Drawdown (3Y)

Largest decline over 3 years

-68.21%

-44.40%

-23.81%

Max Drawdown (5Y)

Largest decline over 5 years

-73.60%

-47.91%

-25.69%

Max Drawdown (10Y)

Largest decline over 10 years

-73.60%

-47.91%

-25.69%

Current Drawdown

Current decline from peak

-68.34%

-19.32%

-49.02%

Average Drawdown

Average peak-to-trough decline

-35.27%

-15.33%

-19.94%

Ulcer Index

Depth and duration of drawdowns from previous peaks

32.47%

9.13%

+23.34%

Volatility

NICE vs. GMED - Volatility Comparison

The current volatility for NICE Ltd. (NICE) is 10.16%, while Globus Medical, Inc. (GMED) has a volatility of 13.69%. This indicates that NICE experiences smaller price fluctuations and is considered to be less risky than GMED based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NICEGMEDDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.16%

13.69%

-3.53%

Volatility (6M)

Calculated over the trailing 6-month period

42.52%

25.33%

+17.19%

Volatility (1Y)

Calculated over the trailing 1-year period

51.48%

49.46%

+2.02%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

39.92%

38.27%

+1.65%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

33.27%

35.68%

-2.41%

Dividends

NICE vs. GMED - Dividend Comparison

Neither NICE nor GMED has paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
GMED
Globus Medical, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NICE
NICE Ltd.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.14%0.76%0.91%

Financials

NICE vs. GMED - Financials Comparison

This section allows you to compare key financial metrics between NICE Ltd. and Globus Medical, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


200.00M300.00M400.00M500.00M600.00M700.00M800.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
766.53M
759.85M
(NICE) Total Revenue
(GMED) Total Revenue
Values in USD except per share items

NICE vs. GMED - Profitability Comparison

The chart below illustrates the profitability comparison between NICE Ltd. and Globus Medical, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
64.4%
0
Portfolio components
NICE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, NICE Ltd. reported a gross profit of 493.46M and revenue of 766.53M. Therefore, the gross margin over that period was 64.4%.

GMED - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Globus Medical, Inc. reported a gross profit of 0.00 and revenue of 759.85M. Therefore, the gross margin over that period was 0.0%.

NICE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, NICE Ltd. reported an operating income of 126.41M and revenue of 766.53M, resulting in an operating margin of 16.5%.

GMED - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Globus Medical, Inc. reported an operating income of 150.39M and revenue of 759.85M, resulting in an operating margin of 19.8%.

NICE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, NICE Ltd. reported a net income of 46.69M and revenue of 766.53M, resulting in a net margin of 6.1%.

GMED - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Globus Medical, Inc. reported a net income of 124.30M and revenue of 759.85M, resulting in a net margin of 16.4%.


Frequently Asked Questions


NICE and GMED have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

GMED has higher volatility (13.69%) compared to NICE (10.16%). In terms of maximum drawdown, NICE dropped -93.23% vs GMED's -47.91%.

GMED currently has the higher Sharpe Ratio (0.71 vs -0.76), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NICE and GMED

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer